Approved adalimumab dosing regimen associated with greater efficacy and lower cost per responder compared with 40 mg every other week dosing without initial 80 mg dose: Analysis of outcomes from adalimumab psoriasis clinical trial database - 07/03/12
Alexa B. Kimball, Department of Dermatology, Harvard Medical School, Boston, MA, United States; Martin Okun, Abbott Immunology, Abbott Laboratories, Abbott Park, IL, United States; Murali Sundaram, Abbott Laboratories, Abbott Park, IL, United States; Parvez M. Mulani, Abbott Laboratories, Abbott Park, IL, United States; Yanjun Bao, Abbott Laboratories, Abbott Park, IL, United States
Le texte complet de cet article est disponible en PDF. Commercial support: This study was funded by Abbott Laboratories. |
Vol 66 - N° 4S1
P. AB185 - avril 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?